ASCO® GI 2025 Insights: Ph3 BREAKWATER Study - Encorafenib + Cetuximab + Chemo in 1L BRAF V600E-Mutant mCRC | VuMedi

Find latest Colon Cancer videos · 400+ videos

This video is featured in the Insights from 2025 ASCO® GI Annual Meeting

Insights from 2025 ASCO® GI Annual Meeting

ASCO® GI 2025 Insights: Ph3 BREAKWATER Study - Encorafenib + Cetuximab + Chemo in 1L BRAF V600E-Mutant mCRC

By Insights from 2025 ASCO® GI Annual Meeting FEATURING Scott Kopetz

By Insights from 2025 ASCO® GI Annual Meeting FEATURING Scott Kopetz

353 views

February 19, 2025

Comments 0

Login to view comments. Click here to Login